Reckitt Benckiser Group (RBGLY) AI Stock Analysis

• Market Cap: $44.73B
• Dividend Yield: 3.33%
• Average Volume (3M): 20.41K
• Price to Earnings (P/E): 12.6
• Beta (1Y): 0.17
• Revenue Growth: 0.29%
• EPS Growth: -14.19%
• Country: US
• Employees: 37,900
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.49
• Shares Outstanding: 3,216,843,000
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 20,409
• PEG Ratio: 0.09
• Price to Book (P/B): 5.08
• Price to Sales (P/S): 2.83
• P/FCF Ratio: 22.79
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 2.81
• Enterprise Value/Gross Profit: 4.63
• Enterprise Value/Ebitda: 8.48
• 1Y Price Target: $14.70
• Price Target Upside: -6.49% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.91
• Revenue Forecast (FY): $17.05B

• Rating: 62 Neutral
• Price Target: $15.50 ▼(-1.40% Downside)
• Action: Downgraded Date: 03/10/26
• Date: Action: Downgraded 03/10/26

The score is held back mainly by weak technical momentum (well below key moving averages with bearish MACD). Fundamentals are steady but not clean—recent revenue and cash-flow pressure plus moderate leverage offset solid profitability. Valuation is a key positive (low P/E and ~3% yield), while the latest call supports a cautiously positive outlook via 2026 growth guidance and cost programs, tempered by near-term margin/FCF and leverage headwinds.

Positive Factors

Innovation & product wins

Sustained R&D and successful new product launches (Durex Intensity, Mucinex NDA) strengthen brand premiumization and category expansion. Durable innovation capability supports long-term pricing power, shelf relevance and higher-margin product mix, aiding revenue resilience across cycles.

Negative Factors

Elevated leverage and near-term rise

Higher leverage reduces financial flexibility to fund investment or weather demand shocks. A rise toward ~2.5x increases refinancing and interest-rate sensitivity, constraining capital allocation and making consistent cash conversion critical to avoid credit pressure over the medium term.

Reckitt Benckiser Group Business Overview & Revenue Model

Company Description

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; di...

Read more

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; di...

How the Company Makes Money

Reckitt makes money primarily by selling branded consumer packaged goods (CPG) to customers worldwide. Its revenue model is largely product-sales driven: the company manufactures (and in some cases outsources the manufacture of) finished goods, ma...

Read more

Reckitt makes money primarily by selling branded consumer packaged goods (CPG) to customers worldwide. Its revenue model is largely product-sales driven: the company manufactures (and in some cases outsources the manufacture of) finished goods, ma...

Reckitt Benckiser Group Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.89B	14.17B	14.61B	14.45B	13.23B
Gross Profit	8.44B	8.60B	8.76B	8.36B	7.69B
EBITDA	4.61B	2.96B	3.19B	3.65B	3.02B
Net Income	3.11B	1.43B	1.64B	2.33B	-32.00M
Balance Sheet
Total Assets	25.02B	25.30B	27.14B	28.74B	26.95B
Cash, Cash Equivalents and Short-Term Investments	1.95B	760.00M	1.39B	1.16B	1.26B
Total Debt	8.42B	8.66B	8.54B	8.88B	9.56B
Total Liabilities	17.26B	18.58B	18.67B	19.26B	19.49B
Stockholders Equity	7.73B	6.70B	8.45B	9.44B	7.40B
Cash Flow
Free Cash Flow	1.72B	2.22B	2.19B	1.95B	1.32B
Operating Cash Flow	2.25B	2.68B	2.64B	2.40B	1.70B
Investing Cash Flow	1.17B	-396.00M	-466.00M	-139.00M	239.00M
Financing Cash Flow	-2.38B	-2.71B	-1.81B	-2.38B	-2.29B

Reckitt Benckiser Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBGLY, the sentiment is Negative. The current price of 15.72 is above the 20-day moving average (MA) of 13.86, above the 50-day MA of 15.59, and above the 200-day MA of 15.37, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 41.98 is Neutral, neither overbought nor oversold. The STOCH value of 70.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBGLY.

Reckitt Benckiser Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PG	74 Outperform	$340.84B	20.05	31.23%	2.92%	1.23%	17.97%
CHD	73 Outperform	$22.78B	27.62	17.16%	1.38%	1.45%	42.04%
UL	69 Neutral	$126.41B	11.85	26.01%	3.74%	-0.30%	-14.60%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
RBGLY	62 Neutral	$44.73B	12.61	38.45%	3.33%	0.29%	-14.19%
CL	61 Neutral	$68.97B	-429.64	431.59%	2.67%	-0.05%	2.49%
KMB	61 Neutral	$32.52B	16.63	155.28%	5.03%	-10.04%	-23.41%